Introduction
Inflammatory bowel disease (IBD) is a complex biologic process, involving genetic, environmental, microbial and immune factors [1, 2] . Growing evidence demonstrated that the microvasculature contributes to chronic inflammation by altering leukocyte recruitment, lymphangiogenesis and angiogenesis leading to tissue remodeling, thus plays a crucial role in the pathophysiology of IBD [3, 4] .
Lymphangiogenesis occurs in adult tissues during pathologic conditions such as inflammation, wound healing and tumor metastasis [5] , and is a recognized hallmark of inflammatory processes in bowel, skin, heart and airways [6, 7] . Lymphangiogenesis could facilitate the resolution of tissue edema and the mobilization of inflammatory cells in acute and chronic inflammatory settings [8, 9] . On the contrary, lymphangiogenesis could also worsen immune diseases such as the rejection response after transplantation [5] . Thus, lymphangiogenic response can be either a detrimental or a beneficial phenomenon in pathologic conditions, which depends on the pathophysiology of the underlying disease [5, 10] . Emerging studies have identified lymphangiogenesis as hallmark features of chronic gut inflammation, and the expansion of vascular population has been hypothesized to play a pathogenic role in IBD [11, 12] .
Vascular endothelial growth factor-C (VEGF-C) is the first powerful lymphangiogenic factor [13, 14] . Lymphangiogenesis is mediated by binding of VEGF-C to VEGFR-3. VEGF-C overexpression markedly induces lymphangiogenesis and reduces the extent of edema in a primary lymphedema mouse model [15] . Additionally, anti-lymphatic treatment in an animal model of IBD has been shown to aggravate inflammation and submucosal edema, and results in an increase of leukocyte infiltration [16] .
Adipose-derived stem cells (ADSCs) are an abundant and readily available population of multipotent progenitor cells that reside in adipose tissue. Their therapeutic use in preclinical studies and experimental clinical trials for several diseases has been well documented because of the potential of secreting growth factors and exosomes [17] [18] [19] [20] [21] . Exosome, a 30-150nm sized extracellular vesicle, containing nucleic acids and proteins, that act as messengers, delivering factors and signaling molecules to close and distant cells [22] [23] [24] .
The top lipid layer and remaining liquid layer were removed after centrifugation at 200g for 10 minutes. The pellet was re-suspended in DMEM supplemented with 10% FBS and filtered through 40 μm nylon cell strainer (BD Falcon, NJ, USA) after lysing the red blood cells. The isolated cells were then plated and expanded in MesenCult-XF culture medium (Stem Cell Technologies, Vancouver, Canada) supplemented with 1% (v/v) penicillin/streptomycin (Gibco, CA, USA) and 2 mM L-glutamine (Gibco). ADSCs culture was maintained at sub-confluent levels (< 80% confluency) at 37°C in 5% humidified CO 2 and passaged using HyQtase (HyClone, USA).
Human dermal lymphatic endothelial cells (LECs) were purchased from Lonza (Basel, Switzerland) and cultured in endothelial growthmedium-2-MV (EGM-2-MV; Lonza) that consisted of endothelial basal medium-2 (EBM-2; Lonza) plus SingleQuots kit (Lonza), according to the manufacturer's instructions.
Preparation of conditioned medium and exosomes
At approximate 80% confluence, ADSCs were washed with PBS thrice and the culture media were replaced with EBM-2 containing 0.1% fatty acid-free bovine serum albumin (Sigma-Aldrich). After 48 h incubation, the medium was collected, filtered through a 0.22 μm filter (EdLab, NY, USA), and used for assays as ADSCs-cm. Exosomes were extracted using the ExoQuick-TCExosome Precipitation Solution (System Biosciences, Mountain View, CA, USA). Briefly, the appropriate volume of ExoQuick-TCExosome Precipitation Solution was added to the CM and refrigerated overnight. The sample was centrifuged at 1500 r.p.m. for 30 min and then at 3000 r.p.m. for 5 min at 4 °C. The exosome pellet was resuspended in approximate 300 μl of cell medium and incubated 72 h with recipient cells. Exosome-deprivated medium was obtained upon 25000 r.p.m. ultracentrifugation for 90 min.
Western blot analysis
After quantification of the protein samples using Micro BCA™ Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA), equivalent amounts of protein (150 µg) were electrophoresed through a 10% SDSpolyacrylamide gel, and then electro-transferred to PVDF membranes (Millipore, Billerica, MA, USA). The blots were incubated for 2h at room temperature with the indicated antibodies (CD63: ab134045, 1:1000, Abcam, CA, USA; HSP70: ab787, 1:1000, Abcam; CD81: ab109201, 1:1000, Abcam; Smad7: H00004092-M02, Novus Biologicals, 1:1000; Smad2/3: ab63672, 1:1000, Abcam; p-Smad2/3: ab63399, 1:1000, Abcam), and then incubated with goat-anti-rabbit/mouse HRP-linked secondary antibody (Santa cruz, CA, UA). Protein signals were visualized using a chemiluminescence substrate (Pierce Chemical, Rockford, IL, USA). The intensity of the selected bands was quantified using Image J software.
Assessment of cell proliferation
Cell proliferation was assessed using Cell Counting Kit-8 (Dojindo, Japan) as our previously described [28] . LECs were plated in 96-well plates in triplicate at approximately 2-5×10 4 cells per well and cultured in 100 mL of EGM-2-MV overnight at 37°C in 5% humidified CO 2 . After the medium was removed LECs were washed with PBS thrice, treated with 100 mL of EBM-2 as a negative control or indicated reagents (exosomes, miR-132 or LY2109761). The numbers of cells per well were measured by the absorbance (450 nm) of reduced WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4 -isulfophenyl)-2H-tetrazolium, monosodium salt) at the indicated time points.
Cell migration assay
LECs migration assay was performed using Transwell chambers with inserts of 8-µm pore size (Corning Costar) as described previously [29] . Briefly, 2 × 10 5 LECs suspended in serum-free media were plated into the upper chamber for migration assay following treatment with indicated reagents, and media supplemented with 10% FBS was placed into the lower chamber. The cells that had migrated through the membrane to the lower surface were fixed, stained and counted after 48 h.
Tube formation assay
Matrigel tube formation assays were carried out as previously described [13] . Briefly, matrigel (BD Biosciences, Bedford, MA, USA) was placed in 24-well plates (100mL/well) and allowed to gel at 37 o C for 30 minutes. 2× 10 5 LECs were then seeded onto the coated wells and cultured with 500 mL of EBM-2, EBM-2 containing indicated reagents at 37°C for 24 h under 5% CO 2 , and then LEC tube formation was assessed Cellular Physiology and Biochemistry
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by microscopy, and each well was photographed. The number of tube branches and total tube length were calculated using the MacBiophotonics Image J software.
Quantitative real-time PCR (qPCR)
Total RNA was extracted from cells using Trizol reagent according to the manufacturer's instruction. Reverse transcription (RT) reactions for mRNA were carried out using the Oligo dT primer and an M-MLV Reverse Transcriptase kit. The specific stem-loop RT primers for miR-132 were designed as previously described [30] . qPCR was performed using a standard SYBR Green PCR kit (Toyobo, Osaka, Japan) protocol on Applied Biosystems 7300 Real Time PCR system (Applied Biosystems, Foster City, CA). U6 and β-actin were used as references for miRNAs and mRNAs, respectively.
miR-132 mimics and inhibitor
Human miR-132 (UAACAGUCUACAGCCAUGGUCG), FAM-labeled miR-132 or 2'-O-methyl modified miR-132 inhibitor (CGACCAUGGCUGUAGAC UGUUA) were purchased from Genepharm (Shanghai, China) and transfected to cells by using Lipofectamine™ 3000 (Invitrogen) according to the manufacturer.
Luciferase reporter assay pGL3 plasmid encoding a luciferase reporter gene was purchased from Promega (Madison, WI). Recombinant plasmid of pGL3-smad7-3'-UTR (wildtype) or pGL3-smad7-3'-UTR-Mutation was constructed in our laboratory. HepG2 cells (2×10 5 cells/well) were plated in a 24-well plate and cotransfected with 40nM of either miR-132 or miRNA control, 20 ng of either pGL3-smad7-3'-UTR or pGL3-smad7-3'-UTR-Mutation, and 2 ng of pRL-TK (Promega, Madison, WI) by using Lipofectamine™ 3000 (Invitrogen). HepG2 cells were collected 48 h after transfection and analyzed using the Dual-Luciferase Reporter Assay System (Promega).
Transmission electron microscopy
For electron microscopy analysis, exosomes were mixed with an equal volume of 4% paraformaldehyde. Sample was then deposited onto Formvar-carbon-coated electron microscopy grids, washed with PBS thrice. Sample was first contrasted in a solution of uranyl oxalate for 5min and then contrasted and embedded in a mixture of 4% uranyl acetate and 2% methyl cellulose for 10 min on ice. The samples were observed under a Hitachi-8100IV transmission electron microscope (Hitachi, Tokyo, Japan) at 100 kV.
Statistical analysis
The data presented are mean ± standard deviation of at least three independent experiments. Averaged data were compared using unpaired Student's t test or one-way ANOVA, followed by the Scheffé test. A two-tailed P value < 0.05 was deemed statistically significant. All statistical analyses were done using SPSS statistical software version 22 for Windows (IBM Corp., USA).
Results

Exosomes from VEGF-C-treated ADSCs (ADSCs/VEGF-C) have higher miR-132 expression
Cell-to-cell communication is an important mechanism for information exchange promoting cell survival, proliferation and migration, and exosomes play a vital role in cellto-cell communication [31, 32] . In the study we investigated the role of exosomes in the interaction of ADSCs with LECs. Exosomes were first isolated from the conditioned media collected from ADSCs/VEGF-C and were characterized by electron microscopy, western blot and qNano analysis. Electron micrographs showed that the collected products had a distinctive cup shape (Fig. 1A) . qNano analysis revealed that the collected products had diameters ranging from 80 to 120 nm (Fig. 1B) . Western blot analysis further showed the expression of the exosomal markers CD63, HSP70 and CD81 (Fig. 1C) but the absence of the cis-Golgi compartment-specific marker GM130 (data not shown).
miRNAs that transfer between living cells that are involved in cell-to-cell communication are frequently encapsulated in exosomes [32] . To identify miRNAs that are transferred by exosomes secreted from ADSCs to LECs, and involved in lymphangiogenesis, we searched PubMed and found 15 functional miRNAs involved in lymphangiogenesis (Table 1 ). The expression of these miRNAs was assayed using qPCR array in exosomes isolated from ADSCs with or without VEGF-C treatment. The qPCR analysis identified 4 upregulated miRNAs and 3 downregulated miRNAs in exosomes from VEGF-C-treated ADSCs compared to exosomes from ADSCs control (Fig.  1D, Table 2 ). Of the 4 upregulated miRNAs, miR-132 was selected to further study because miR-132 possessed the most potential of promoting LECs proliferation (Fig. 2) .
Direct transfer of miR-132 from ADSCs to LECs
To determine whether miR-132 can be directly transferred from ADSCs to LECs, ADSCs were transiently transfected with miR-132 or control, then the conditioned medium, changed 8 h post-transfection, was collected from transfected cells at 48 h and processed for exosomal purification. The expression level of miR-132 was assayed by qPCR in transfected cells and in the isolated exosomes. As shown in Fig. 3A and B, miR-132 level was significantly upregulated in miR-132-treated ADSCs and its exosomes compared to control. Fig. 3C showed that the incubation with ADSCs-secreted exosomes results in increase of miR-132 level in recipient LECs compared to control, indicating that the recipient LECs could uptake the exosomes and their cargo. To further determine whether miR-132 can be directly transferred from ADSCs to LECs, ADSCs were transiently transfected with fluorescein amidite (FAM)-tagged miR-132, and were co-cultured with LECs. Confocal microscopy detected FAM-labeled miR-132 in the LECs cocultured with miR-132-transfected ADSCs but not in those co-cultured with mock-transfected ADSCs, suggesting that miR-132 was transferred from ADSCs to LECs (Fig. 3D) . Exosome was then isolated from conditioned media collected from ADSCs that had been transfected with FAM-tagged miR-132 or control and was added to LECs. Confocal microscopy revealed fluorescently labelled signals in the LECs incubated with exosomes obtained from FAM-tagged miR-132-transfected cells compared to control (Fig.  3E ), confirming that miR-132 was transferred from ADSCs to LECs via exosomes.
Exosomes from-ADSCs/VEGF-C (exosome-ADSCs/ VEGF-C) promote LECs proliferation, migration and tube formation
We then investigated whether exosomes-ADSCs/ VEGF-C promotes lymphangiogenesis by regulating LECs proliferation, migration and tube formation. LECs were treated with exosome-ADSCs or exosomeADSCs/VEGF-C and cell proliferation was assayed using CCK-8. Fig. 4A showed that exosome-ADSCs/ VEGF-C promotes LECs proliferation compared to exosome-ADSCs or control. We also assessed the role of exosome-ADSCs/VEGF-C in the regulation Fig. 4B and C showed that exosome-ADSCs/ VEGF-C significantly promoted LECs migration compared with exosomeADSCs. We further assessed the role of exosome-ADSCs/VEGF-C in the regulation of LECs tube formation. As shown in Fig. 5A and B, exosome-ADSCs/VEGF-C promotes tube formation of LECs compared with exosome-ADSCs. Importantly, pretreatment with miR-132 inhibitor attenuated the effect of these exosomes on LECs proliferation, migration and tube formation ( Fig. 4 and Fig. 5 ). These data demonstrated that exosomal transfer of miR-132 from ADSCs to LECs promoted LECs proliferation, migration and tube formation.
miR-132 promotes lymphangiogenic response by regulating TGF-β/Smad signaling Transforming growth factor-β (TGF-β) is known to play an important role in lymphangiogenesis [33, 34] , but the precise relationship between TGF-β and lymphangiogenesis is not well known. Additionally, the correlation of miR-132 with TGF-β/Smad signaling was revealed in several cancer, including glioma [35] , prostate cancer [36] and non-small cell lung cancer [37] . Therefore, we next investigated whether miR-132 promotes lymphangiogenic response by regulating TGF-β/Smad signaling. As shown in Fig. 6A , miR-132 overexpression promoted LECs proliferation, whereas Ly2109761 (a specific inhibitor of TGF-β/Smad) treatment attenuated the effect of miR-132 on LECs proliferation. Similarly, Ly2109761 attenuated miR-132-induced migration and tube formation of LECs (Fig. 6B-D) .
We then investigated whether miR-132 directly regulates TGF-β/Smad signaling. Fig. 7A showed that overexpression of miR-132 in LECs increased the level of p-Smad2/3, whereas Ly2109761 treatment inhibited miR-132-induced increase of p-Smad2/3. To identify the molecular mechanism of miR-132 involved TGF-β/Smad pathway, we assayed the expression level of main components (TGFβRI, TGFβRII, smad1, smad2, smad3, smad4, smad5 and smad7) in TGF-β/Smad pathway. As shown in Fig. 7B , smad7 expression was significantly inhibited following miR-132 overexpression among these components of TGF-β/Smad pathway. To further verify that miR-132 directly targets smad7 and inhibits its expression, we constructed luciferase reporter vector containing 3'-UTR of smad7. The reporter assay showed that miR-132 was able to markedly inhibit luciferase expression, whereas mutation 5 cells LECs were plated in 96-well plates and cultured in 100 L of EGM-2-MV overnight. After the medium was removed LECs were treated with 100 mL of EBM-2 control, EBM-2 containing exosomeADSCs, exosome-ADSCs/VEGF-C or exosome-ADSCs/VEGFC+miR132 inhibitor. Cell proliferation was assayed by using CCK-8 and at the indicated time points. * p<0.05. (B) 2 × 10 5 LECs suspended in serum-free media were plated into the upper chamber for migration assay after treatment with indicated reagents, including EBM-2 control, exosomeADSCs, exosome-ADSCs/VEGF-C or exosome-ADSCs/VEGFC+miR132 inhibitor. Media supplemented with 10% FBS was placed into the lower chamber. The cells that had migrated through the membrane to the lower surface were fixed, stained and counted after 48 h. * p<0.05. (Fig. 7C) . Forced expression of miR-132 significantly inhibited the smad7 protein level, whereas miR-132 inhibition resulted in an increase of smad7 protein level in LECs (Fig. 7D) . It is well known that smad7 negatively regulates TGF-β/Smad signaling. Therefore current data suggest that miR-132 enhances the activation of TGF-β signaling, at least in part by inhibiting smad7.
Discussion
In the present study, the role of ADSCs in VEGF-C-dependent lymphangiogenesis and its underlying mechanism were investigated in vitro. The current data demonstrate that (i) Exosomes from ADSCs/VEGF-C have higher miR-132 expression, (ii) miR-132 can be directly transfer from ADSCs to LECs, (iii) Exosomes from ADSCs/VEGF-C promote LECs proliferation, migration and tube formation, (iv) miR-132 promotes lymphangiogenic response by regulating TGF-β/Smad signaling. These results reveal the interaction of ADSCs with LECs in VEGF-Cdependent lymphangiogenesis and identify exosome-derived miR-132 play an important role in lymphangiogenesis by regulating TGF-β/Smad signaling. LECs were plated in 96-well plates and cultured in 100 mL of EGM-2-MV overnight. After the medium was removed LECs were treated with 100 mL of EBM-2 control, EBM-2 containing miR-132, miR-132 plus LY2109761. Cell proliferation (A) and migration (B) were assayed. * p<0.05. (C and D) 2 × 10 5 LECs were seeded onto the coated wells and cultured with 500 mL of EBM-2, EBM-2 containing miR-132, miR-132 plus LY2109761. LEC tube formation was assessed by microscopy, and each well was photographed. * p<0.05. 5 LECs were seeded onto the coated wells and cultured with 500 mL of EBM-2, EBM-2 containing exosome-ADSCs, exosome-ADSCs/VEGF-C or exosomeADSCs/VEGF-C+miR132 inhibitor. LEC tube formation was assessed by microscopy, and each well was photographed. The number of tube branches and total tube length were calculated using the MacBiophotonics Image J software. Cellular Physiology and Biochemistry
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Modified cell-based angiogenic therapy is a promising novel strategy for several diseases such as ischemic heart, limb diseases and inflammation-related diseases [38] . Currently, major studies focus on myoblast or mesenchymal stem cells (MSCs) transplantation. However emerging studies showed extensive expansion of MSCs may contain the risk for clonal selection and subsequent malignant transformation [39, 40] . Adipose-derived stem cells (in contrast to bone marrow) are abundantly available and can be easily harvested during liposuction or surgery. Due to high paracrine activity and availability ADSCs are thought be a preferable cell type for the therapy of several diseases. The therapeutic potential of modified ADSC is gradually being revealed [38] . Shevchenko et al. reported that ADSCs modified with VEGF165 present a more efficient angiogenic response in ischemic skeletal muscle [38] . In the study, we investigated the role of ADSCs in VEGF-C-dependent lymphangiogenic response. VEGF-C-treated ADSCs secrets exosomes, and the exosomes from ADSCs/VEGF-C promote LECs proliferation, migration and tube formation.
Emerging studies reported that cell-to-cell communication is an important mechanism for information exchange promoting cell survival via microvesicles, including ectosomes (100-1, 000 nm) and exosomes (30-150 nm) [41] . Exosomes are extracellular membrane vesicles secreted from almost all human cell types [42] . Secreted exosomes can be engulfed by tissues locally or carried in biological fluids to distant sites in the body. Target cells can engulf exosomes through endocytosis, resulting in the intracellular release of bioactive molecules. We thus investigated whether exosomes from ADSCs/VEGF-C promotes lymphangiogenesis by regulating LECs proliferation, migration and tube formation. Our results showed that cmADSCs/VEGF-C or exosome-ADSCs/VEGF-C promotes LECs proliferation, migration and tube formation.
Studies have shown that exosomes contain non-coding RNAs such as miRNAs. miRNAs that transfer between living cells that are involved in cell-to-cell communication are [34] . Here we demonstrated that exosomes from VEGF-C-treated ADSCs had higher miR-132 expression. Furthermore, miR-132 could be directly transferred from ADSCs to LECs by the mediation of exosomes. Functionally, miR-132 promoted lymphangiogenic response, whereas miR-132 inhibition suppressed LECs proliferation, migration and tube formation. TGF-β plays an important role in lymphangiogenesis [33, 34] , and the correlation of miR-132 with TGF-β/Smad signaling was revealed in several cancer [35, 37] . We thus investigated whether miR-132 promoted lymphangiogenic response by regulating TGF-β/Smad signaling. Current data demonstrated that miR-132 overexpression promoted lymphangiogenic response, whereas Ly2109761 (a specific inhibitor of TGF-β/Smad) treatment partially inhibited the effect of miR-132 on LECs proliferation, migration and tube formation. Finally, we demonstrated that miR-132 enhances the activation of TGF-β signaling, at least in part by inhibiting smad7.
Conclusion
ADSCs treated with VEGF-C results in a more efficient lymphangiogenic response by secreting exosomes and may provide a new therapeutic modality for boosting the efficacy of therapeutic lymphangiogenesis. 
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